NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded at HC Wainwright

NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by HC Wainwright to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q3 2026 earnings at ($0.59) EPS.

Several other equities research analysts have also issued reports on the company. The Goldman Sachs Group lifted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Needham & Company LLC lifted their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday. Finally, Stifel Nicolaus upped their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $34.63 on Thursday. The business’s 50-day moving average is $34.00 and its 200-day moving average is $32.45. The company has a market capitalization of $3.93 billion, a price-to-earnings ratio of -20.02 and a beta of 0.06. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 25.99%. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.92 million. Equities research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total value of $1,037,061.60. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $774,425.40. The trade was a 57.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the transaction, the insider directly owned 73,481 shares of the company’s stock, valued at $2,443,243.25. This represents a 7.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 298,647 shares of company stock worth $10,236,050. 20.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Capital World Investors increased its position in NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after acquiring an additional 1,434,986 shares during the period. Jennison Associates LLC grew its position in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Duquesne Family Office LLC increased its holdings in shares of NewAmsterdam Pharma by 131.2% during the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after purchasing an additional 1,091,525 shares during the period. Castle Hook Partners LP acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $38,062,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.